US 7,576,050 B2
	GLP-1 exendin-4 peptide analogs and uses thereof
Nigel Greig, Phoenix, Md. (US); Josephine Egan, Baltimore, Md. (US); Maire Doyle, Baltimore, Md. (US); Harold Holloway, Middle River, Md. (US); and Tracy Ann Perry, Baltimore, Md. (US)
Assigned to The United States of America as represented by the Department of Health and Human Services, Washington, D.C. (US)
Appl. No. 10/485,140 PCT Filed Jul. 30, 2002, PCT No. PCT/US02/24141 § 371(c)(1), (2), (4) Date Apr. 01, 2004, PCT Pub. No. WO03/011892, PCT Pub. Date Feb. 13, 2003.
Claims priority of provisional application 60/309076, filed on Jul. 31, 2001.
Prior Publication US 2004/0242853 A1, Dec. 02, 2004
Int. Cl. A61K 38/26 (2006.01); C07K 14/605 (2006.01)

U.S. Cl. 514—2  [514/12; 530/308; 530/324]

15 Claims

1. A method of treating a subject with a neurodegenerative disease or of reducing one or more symptoms of a neurodegenerative disease in a subject in need thereof, wherein the neurodegenerative disease is peripheral neuropathy, comprising administering to the subject a therapeutically effective amount of a polypeptide comprising GLP-1, exendin-4, or a therapeutically effective GLP-1 or exendin-4 analogue, wherein the polypeptide binds to and activates a receptor that binds GLP-1, exendin-4, or both.